Design Therapeutics (DSGN) Earnings Date & Reports

Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

DSGN is expected to report earnings to rise 19.55% to -34 cents per share on August 10

Design Therapeutics DSGN Stock Earnings Reports

Q2'26

Est.

$-0.35

Q1'26

Beat

by $0.03

Q4'25

Beat

by $0.06

Q3'25

Beat

by $0.04

Q2'25

Missed

by $0.04

The last earnings report on April 28 showed earnings per share of -28 cents, beating the estimate of -31 cents. With 57.30K shares outstanding, the current market capitalization sits at 833.80M.

View a ticker or compare two or three

Compare

DSGN

Setup

Daily Signal:

Description

Gain/Loss:

Interact to see
Advertisement

A.I.Advisor

published price charts

Last 5 trading days

View AI-Driven Trading for DSGN